Pfizer Inc
NYSE: PFE
$26.17
+$0.52 (+2.0%)
Closing Price on November 25, 2024
PFE Articles
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
Published:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Published:
As of the most recently reported period, short sellers favored Pfizer, Exxon and Intel above all other Dow Jones industrial stocks, although two of them soon will be dropped from the index.
Published:
The Dow Jones industrial average changes look a bit strange, and the real effort behind those changes may simply be to juice the index higher in the future than due to the reasons cited.
Published:
Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
Published:
After the caution seen in the prior period, short sellers seemed to find some focus. As of the most recently reported period, those sellers favored Pfizer, Exxon and Intel above all other Dow stocks.
Published:
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published:
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate Technology, Sonos, Starbucks and T-Mobile.
Published:
Pfizer released a better than expected second-quarter earnings report and increased its guidance before the markets opened on Tuesday.
Published:
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
Published:
As of the most recently reported period, short sellers still favored Exxon, Pfizer and Microsoft above all other Dow stocks.
Published:
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
Published:
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
Published: